Source LDPath is a flexible and trusted extension to your histopathology laboratory, supporting you to accelerate turnaround times for reporting and decrease backlogs.
In 2023, we successfully reported over 260,000 cases with our NHS histopathology partners, and we are delighted to announce that we have further increased our capacity this year to support your department and provide better patient care.
We have capacity to support:
GMP compliant materials and support for ATMP manufacturing.
AMSBIO is dedicated to helping its customers seamlessly translate their cutting-edge research into production products for clinical therapy. A comprehensive new resource has been added to the website, where you will find links to all the information you need on how AMSBIO can help you better understand and set up a GMP manufacturing process.
Optical genome mapping (OGM) is a workflow that combines various technologies for one purpose: to reveal structural variation in a way that’s never been done before.
Capture and accurately map the entire genome construct, giving a high-resolution view of genome structure with OGM. Structural variations in the form of deletions, duplications, translocations and inversions can be directed imaged, and the analytical gap filled from sequencing technology alone.
Bionano advanced Saphyr imaging instrument
Source LDPath have further optimised their histopathology courier service to improve on their already market-leading turnaround times. The new and improved courier network has recently launched and will fully replace old courier routes by Monday, May 20th 2024.
Existing clients do not need to do anything and operations will continue as normal.
Samples will travel directly from clinic to laboratory – for a fast and seamless journey via the new courier, Nexus.
These changes will also allow new deliveries to the laboratory on Saturdays for even faster turnaround times.
Asymchem Laboratories (Tianjin) Co., Ltd. announced today that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe. Asymchem will continue to operate the site in Sandwich, Kent, as a clinical small molecule development and manufacturing facility to meet global client demands for pharma services and supply.
We are excited to see that One Nucleus Corporate Patron, AstraZeneca, has announced an ambitious goal to achieve $80 billion in annual revenue by 2030, a significant increase from $45 billion in 2023. This growth will be driven by expanding their oncology, biopharmaceuticals and rare disease portfolios and launching 20 new medicines by the end of the decade. Additionally, AstraZeneca plans to sustain growth beyond 2030 by investing in transformative new technologies.
Read the latest update on ON Helix 2024 here
The Life Sciences Catalyst Business Lounge, designed to be a regional hotspot for start-ups and world-leading businesses in the life sciences sector, has been opened by Deloitte Cambridge.
The Life Sciences Catalyst Business Lounge is based within Deloitte Cambridge’s existing office and located on the 1st floor.
• Company will host a CEO and key opinion leader webinar at 14.30 BST
• AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI
• Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI